Barclays’s Takeda Pharmaceutical TAK Stock Holding History

Barclays’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,200	Closed	-$81.1K	–	5422
2025 Q4	$81.1K	Buy	+5,200	New	+$74.3K	﹤0.01%	4631
2021 Q2	–	Sell	-150,000	Closed	-$2.74M	–	5069
2021 Q1	$2.74M	Sell	150,000 -154,224	-51%	-$2.77M	﹤0.01%	2022
2020 Q4	$5.54M	Hold	304,224	–	–	﹤0.01%	1462
2020 Q3	$5.43M	Sell	304,224 -1,200	-0.4%	-$21.9K	﹤0.01%	1346
2020 Q2	$5.48M	Buy	305,424 +40,188	+15%	+$721K	﹤0.01%	1309
2020 Q1	$4.03M	Sell	265,236 -26,359	-9%	-$478K	﹤0.01%	1656
2019 Q4	$5.75M	Buy	291,595 +21,600	+8%	+$413K	﹤0.01%	1858
2019 Q3	$4.64M	Sell	269,995 -6,304	-2%	-$109K	﹤0.01%	1916
2019 Q2	$4.89M	Buy	276,299 +100,673	+57%	+$1.83M	﹤0.01%	1886
2019 Q1	$3.58M	Buy	+175,626	New	+$3.53M	﹤0.01%	1965

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Barclays's TAK Position: Q2 2026 in Review

Barclays increased its Takeda Pharmaceutical (TAK) stake by 286% in Q2 2026, buying an estimated $58.8K and bringing the position to 4,792 shares worth $76.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4162.

Barclays first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $27.9M in Q1 2023. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Barclays held 4,792 shares of Takeda Pharmaceutical worth $76.8K as of Q2 2026.
Barclays bought 3,551 Takeda Pharmaceutical shares in Q2 2026, an estimated $58.8K.
Takeda Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4162 holding.
Barclays first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
Barclays's Takeda Pharmaceutical position peaked at $27.9M in Q1 2023.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.